Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- PAFSC’s Second Committee Recommends Approval for Pfizer’s JAK Inhibitor Xeljanz, Others
March 14, 2013
- LDP Policy Subcommittee Demands Ban on Mixed Healthcare in TPP Talks
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Reports 1st Death Following Quadruple Vaccine Immunization, Causality is Under Investigation
March 13, 2013
- Japan Health Insurance Association President Tsuyoshi Kobayashi Points Out that Price Competition Will Not Work If Prices Are Set Equally
March 12, 2013
- Pricing Rules for Innovative Drugs Will Not Be a Priority in Discussions by Regulatory Reform Council
March 12, 2013
- PAFSC’s First Committee Recommends Approval for OAB Drug Neoxy Tape
March 11, 2013
- Health Sciences Council to Discuss Protocol for Clinical Trial Using iPS Cells
March 11, 2013
- Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug
March 8, 2013
- Drug Safety Monitoring Program of RMPs to Be Announced via PMDA’s Website: PFSB Notification
March 7, 2013
- Over 40% of Preliminary Meetings Proceed to Face-to-Face Consultation Meetings in Regulatory Strategy Consultation Services: Report
March 7, 2013
- MHLW to Announce Revised GVP, GPSP Ordinances “Early Next Week”: Director Tawaragi of PFSB
March 6, 2013
- MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
- MHLW Aims to Submit Bill to Amend PAL During Current Diet Session: PFSB Director-General Jun Ebata
March 6, 2013
- PAFSC Second Committee to Discuss Pfizer’s Xeljanz and Bayer’s Stivarga on March 13
March 5, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of New Parkinson’s Disease Agent and DPP-4 Inhibitor Onglyza
March 5, 2013
- Health and Education Ministries along with Drug Makers to Start Intractable Disease Research using iPS Cells
March 5, 2013
- Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
- Generic Share by Volume Rose to 28.7% in September 2012, MHLW Reports
March 4, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…